首页|Multiple myeloma survival in New South Wales,Australia,by treatment era to 2020

Multiple myeloma survival in New South Wales,Australia,by treatment era to 2020

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Objective:Australia has relatively high multiple myeloma(MM)incidence and mortality rates.Advancements in MM treatment over recent decades have driven improvements in MM survival in high-income countries;however,reporting in Australia is limited.We investigated temporal trends in population-wide MM survival across 3 periods of treatment advancements in New South Wales(NSW),Australia.Methods:Individuals with an MM diagnosis in the NSW Cancer Registry between 1985 and 2015 with vital follow-up to 2020,were categorized into 3 previously defined treatment eras according to their diagnosis date(1985-1995,chemotherapy only;1996-2007,autologous stem cell transplantation;and 2008-2015,novel agents including proteasome inhibitors and immunomodulatory drugs).Both relative survival and cause-specific survival according to Fine and Gray's competing risks cumulative incidence function were calculated by treatment era and age at diagnosis.Results:Overall,11,591 individuals were included in the study,with a median age of 70 years at diagnosis.Five-year relative survival improved over the 36-year(1985-2020)study period(31.0%in 1985-1995;41.9%in 1996-2007;and 56.1%in 2008-2015).For individuals diagnosed before 70 years of age,the 5-year relative survival nearly doubled,from 36.5%in 1985-1995 to 68.5%in 2008-2015.Improvements for those>70 years of age were less pronounced between 1985-1995 and 1996-2007;however,significant improvements were observed for those diagnosed in 2008-2015.Similar overall and age-specific patterns were observed for cause-specific survival.After adjustment for gender and age at diagnosis,treatment era was strongly associated with both relative and cause-specific survival(P<0.0001).Conclusions:Survival of individuals with MM is improving in Australia with treatment advances.However,older age groups continue to experience poor survival outcomes with only modest improvements over time.Given the increasing prevalence of MM in Australia,the effects of MM treatment on quality of life,particularly in older age,warrant further attention.

Multiple myelomacancer epidemiologysurvival analysiscompeting risk analysisAustralia

Eleonora Feletto、Qingwei Luo、Anna Kelly、Marianne Weber、David Goldsbury、Katherine Barron、Karen Canfell、Xue Qin Yu

展开 >

The Daffodil Centre,The University of Sydney,A Joint Venture with Cancer Council NSW,Sydney NSW 2006,Australia

Cancer-Patient Population Projections project funded by a Medical Research Future Fund(MRFF)Preventive and Public Health ResNational Health and Research Council of Australia Leadership Investigator GrantsNational Health and Research Council of Australia Leadership Investigator Grantsco-PI of an investigatorinitiated trial of cervical screening,"Compass,"Australian Centre for the Prevention of Cervical Cancer(ACPCC)governmentfunded notforprofit charityAustralian governmentACPCC has received equipment and a funding contributions from Roche Molecular Diagnostics,USAco-PI on a major implementation programElimination of Cervical Cancer in the Western PacificMinderoo Foundation and equipment donations from Cepheid Inc

MRF1200535NHMRCGrant No.APP1194679

2024

10.20892/j.issn.2095-3941.2024.0177

癌症生物学与医学(英文版)
中国抗癌协会

癌症生物学与医学(英文版)

CSTPCD
影响因子：1.07
ISSN：2095-3941
年,卷(期)：2024.21(8)
  • 1